

The interest of the team of Hepatitis C Venezuela AC, is to make known by different means of communication that hepatitis C virus (HCV) is treated, forms of transmission or contamination, ways to prevent, appropriate and timely treatment to avoid serious complications Which brings this entity if not diagnosed in time.
We are fighting for the approval and supply of the new direct antivirals to all of our affected.
Helping the well-being and quality of life of the sick.
Keep informed and updated to any user who enters the page in the search of information on the subject at hand.
It is of great importance to educate and inform everyone who is unaware of the cause, risk factors and treatments of this disease, it is for this reason that it seems relevant to give information talks at the level of schools, colleges, universities, public and private offices, Information campaigns in avenues, collective transport, metro, mass media such as radio, tv, etc.
When we refer to the population in general, it is by the way the disease spreads, which is through direct contact with contaminated blood, for example: piercing, tattoos, manicurist, surgeries, surgical and dental procedures, blood transfusions, Intravenous drugs, etc.
By being informed, our participants, patients and users will become the main disseminators of prevention throughout the national territory.
Hepatitis and PWID/harm reduction
11:35 – 11:40
Chair: WHO – Intro and set the scene.
11:40 – 11:55
Co-chair: EMCDDA – Monitoring viral hepatitis elimination among PWID in Europe.
11:55 – 12:00
ID 29: Ema Pos (not yet registered)
Title: If the mountain won’t come to Mohammed: lessons from a decentralized Infectious Disease consultation.
12:05 – 12:10
ID 152: Brian Conway (Registered in person)
Title: Community Pop-up Clinic: Cascade of Care and HCV Treatment of Vancouver’s inner-city PWID Populations.
12:10 – 12:15
ID 212: Jasmine West (not yet registered)
Title: From lived experience to lived expertise: a syndemic approach.
12:15 – 12:20
ID: 299 Mercy Nyakowa (Registered in person)
Title: HCV and HBV prevalence and associated risk factors among people who inject drugs (PWIDs) in Kenya
12:20 – 12:25
ID: 133 Nalinikanta Rajkumar (Registered in person)
Title: Rapid regimen of HBV vaccination: Does it work for high risk groups?
12:25 – 12:30
Q&A and closing remarks
tHIS
IS
BEN’S
BIG
TEST
effective case finding strategies
Supported by Vir Biotechnology, Inc
During this session you will hear from hepatitis Delta expert, Dr. Maria Buti, and a patient who has lived with hepatitis Delta in a panel discussion moderated by Dr. Carey Hwang, Chief Medical Officer (interim) of Vir Biotechnology. This panel will inform perspectives on patient needs, opportunities for enhanced screening, and strengthening linkages to care.
Session Agenda
14:40 – 14:45
Panel overview and introductions facilitated by Dr Carey Hwang (Vir Biotechnology)
14:45 – 15:05
Panel discussion: Dr Maria Buti (University Hospital Vall d’Hebron, Spain), Milanka Barbosa, Dr Carey Hwang (Chief Medical Officer interim), Vir Biotechnology
15:05 – 15:10
Final remarks and close